Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428538 | 1.00 | GABRA1 (0.50) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL4659907 | 0.97 | GABRA1 (0.48) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL5713283 | 0.83 | HTT (0.44) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL1044900 | 0.81 | HTT (0.47) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL1368986 | 0.81 | HTT (0.43) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL3293339 | 0.81 | HTT (0.43) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL3296582 | 0.81 | HTT (0.43) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL4427313 | 0.80 | CA1 (0.46) | GABRA1GABRB2GABRG2GABRB3CYP3A4 | |
| SCHEMBL1454663 | 0.79 | CYP3A4 (0.45) | CYP3A4LMNACYP1A2HIF1AHTT | |
| SCHEMBL22416798 | 0.79 | HTT (0.42) | GABRA1GABRB2GABRG2GABRB3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | UNIV ARKANSAS (US) | 2026-01-29 | — | — | US | claimed |
| CN-111205317-A | Novel [ ONN ] tridentate fourth subgroup metal complex and preparation method and application thereof | 山东京博中聚新材料有限公司 | 2020-05-29 | — | — | CN | claimed |
| CN-106146710-B | Cationic polymerization method | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-106146710-A | Cationic polymerization method | 中国石油化工股份有限公司 | 2016-11-23 | — | — | CN | claimed |
| CN-102304056-B | 3-methyl-4-aryl-3-alkenyl-butyryl-pentafluoroaniline derivatives and preparation method thereof | UNIV ZHEJIANG | 2013-12-11 | — | — | CN | claimed |
| CN-102304056-A | 3-methyl-4-aryl-3-alkenyl-butyryl-pentafluoroaniline derivatives and preparation method thereof | UNIV ZHEJIANG | 2012-01-04 | — | — | CN | claimed |
| JP-7278031-A | — | — | None | — | — | JP | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | UNIV ARKANSAS (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-4996372-A | In a basic aqueous solution, then acid cleaving in the presence of hydrogen peroxide | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| EP-0144729-B1 | 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-11-08 | — | — | EP | disclosed |
| US-4681879-A | 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-07-21 | — | — | US | disclosed |
| US-4608374-A | 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0144729-A1 | 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0005385-B1 | PIPERAZINE METHANE IMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | LAROCHE NAVARRON S.A. Société dite: (FR) | 1982-09-01 | — | — | EP | disclosed |
| US-3962307-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | GABRA1 474/4885GABRB2 697/4885GABRG2 745/4885 |
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | GABRA1 2982/4885GABRB2 923/4885GABRG2 1221/4885 |
| US-12338245-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | GABRA1 484/4885GABRB2 417/4885GABRG2 695/4885 |
| US-12577251-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, CHRNA6, NR3C2 | GABRA1 103/4885GABRB2 59/4885GABRG2 181/4885 |
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | KCNK5, KCNA7, KCNA4 | GABRA1 1607/4885GABRB2 1007/4885GABRG2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.